Nivolumab

Nivolumab plus ipilimumab induced durable responses among a subset of men with metastatic castration-resistant prostate cancer, according to results of the phase 2 CheckMate 650 study published in Cancer Cell.

This year has seen some groundbreaking advances in genitourinary oncology, particularly in the fields of prostate, kidney and urothelial cancers.

The FDA granted priority review to nivolumab in combination with cabozantinib for treatment of advanced renal cell carcinoma.

Nivolumab did not improve overall survival compared with gemcitabine or pegylated liposomal doxorubicin in platinum-resistant ovarian cancer; however, it was better tolerated, according to results presented at ESMO Virtual Congress 2020.

In more than 6 years as a chief medical editor for HemOnc Today, only a few subjects have prompted me to write more than one editorial.

A recent study showed that quadrivalent HPV vaccination substantially reduced the risk for invasive cervical cancer. It was the top story in hematology/oncology last week.

The addition of nivolumab to neoadjuvant chemotherapy significantly improved the pathologic complete response rate among patients with resectable non-small cell lung cancer, according to topline data released by the agent’s manufacturer.

The FDA approved nivolumab in combination with ipilimumab for the treatment of adults with unresectable malignant pleural mesothelioma, the first drug regimen approved for this population in 16 years.

Adjuvant nivolumab significantly prolonged DFS compared with placebo among patients with resected esophageal and gastroesophageal junction cancer, according to results of the CheckMate 577 trial presented during ESMO Virtual Congress 2020.

The addition of nivolumab to first-line chemotherapy significantly improved PFS, but not OS, for patients with advanced or recurrent HER2-negative gastric and gastroesophageal junction cancer, according to phase 3 study findings.